Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mochida Will Groom Lialda into Flagship Quickly: President
January 27, 2017
- Daiichi Sankyo Espha to Launch Micardis AG, Will Actively Handle Competitors’ Products
January 27, 2017
- Sumitomo Dainippon Completes Tolero Acquisition
January 27, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in OS as Liver Cancer 1st Line Treatment
January 27, 2017
- Pfizer Adjusts Shipments for Tazopipe, Voluntarily Recalls Metformin Generics
January 27, 2017
- Biogen Japan to Make New Start as MS Powerhouse after Hemophilia Spin-off
January 25, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
- Takara Bio to Initiate PI/II Trial of Gene Therapy for Synovial Sarcoma
January 25, 2017
- Rohto Anticipates Large-Scale Stem Cell Production Using Automated System, Will Submit Clinical Trial Plan for Cirrhosis this Spring
January 25, 2017
- Napabucasin Add-On Shows Efficacy in Colorectal Cancer: Sumitomo Dainippon
January 24, 2017
- Takecab Most Heavily Pitched Drug in HP Market in November: Anterio
January 24, 2017
- Kansai Medico Issues Apology over Harvoni Counterfeits
January 24, 2017
- Ferring Speeding Up R&D in Core Sectors, Positive on Licensing and M&A: Japan CEO
January 23, 2017
- Stivarga Gets Priority Review for 2nd-Line Liver Cancer Treatment
January 23, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Dismissed: Towa
January 23, 2017
- BMS-Ono Pair, Merck Settle Keytruda Patent Suits
January 23, 2017
- Opdivo Extends OS in Advanced Gastric Cancer: Ono
January 23, 2017
- Takeda Taps NY Biotech to Develop Its Pediatric Epilepsy Med
January 20, 2017
- Daiichi Sankyo’s 2nd ADC Now in Japan PI/II for HER3-Positive Breast Cancer
January 20, 2017
- Hiroshi Kasamoto Named as Bioverativ Japan President
January 20, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…